{"title": "Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review", "doi": "10.1101/2020.03.04.20031401", "citation_id": "2020.03.04.20031401v1", "date": "2020-03-08", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.04.20031401", "abstract": "<p>Objectives:\nTo examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core outcome set (COS) in this field.\nDesign:\nThis study is a review.\nData sources:\nDatabases of ICMJE-accepted clinical trial registry platform were searched on February 14, 2020.\nEligibility Criteria:\nRandomized controlled trials (RCTs) and non-RCTs of COVID-19 were considered.Conditions of patients include common type, severe type or critical type. Interventions include traditional Chinese medicine (TCM) and Western medicine. We excluded trials that for discharged patients, psychological intervention and complications of COVID-19.\nData extraction and synthesis:\nThe general information and outcomes, outcome measurement instruments and measurement times were extracted. The results were analysed by descriptive analysis. \nResults:\n19 registry platforms were searched. A total of 97 protocols were included from 160 protocols. For protocols of TCM clinical trials, 76 outcomes from 16 outcome domains were reported, and almost half (34/76, 44.74%) of outcomes were reported only once; the most frequently reported outcome was time of SARS-CoV-2 RNA turns to negative. 27 (27/76, 35.53%) outcomes were provided one or more outcome measurement instruments. 10 outcomes were provided one or more measurement time frame. For protocols of western medicine clinical trials, 126 outcomes from 17 outcome domains were reported; almost half (62/126, 49.21%) of outcomes were reported only once; the most frequently reported outcome was proportion of patients with negative SARS-CoV-2. 27 outcomes were provided one or more outcome measurement instruments. 40 (40/126, 31.75%) outcomes were provided one or more measurement time frame.\nConclusion:\nOutcome reporting in protocols of clinical trials of COVID-19 is inconsistent. Thus, developing a core outcome set is necessary. \nKeywords: Outcomes; clinical trials, COVID-19; review.</p>", "twitter_description": "Objectives: To examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core outcome set (COS) in this field. Design: This study is a review. Data sources: Databases of ICMJE-accepted clinical trial registry platform were searched on February 14, 2020. Eligibility Criteria: Randomized controlled trials (RCTs) and non-RCTs of COVID-19 were considered.Conditions of patients include common type, severe type or critical type. Interventions include traditional Chinese medicine (TCM) and Western medicine. We excluded trials that for discharged patients, psychological intervention and complications of COVID-19. Data extraction and synthesis: The general information and outcomes, outcome measurement instruments and measurement times were extracted. The results were analysed by descriptive analysis. Results: 19 registry platforms were searched. A total of 97 protocols were included from 160 protocols. For protocols of TCM clinical trials, 76 outcomes from 16 outcome domains were reported, and almost half (34/76, 44.74%) of outcomes were reported only once; the most frequently reported outcome was time of SARS-CoV-2 RNA turns to negative. 27 (27/76, 35.53%) outcomes were provided one or more outcome measurement instruments. 10 outcomes were provided one or more measurement time frame. For protocols of western medicine clinical trials, 126 outcomes from 17 outcome domains were reported; almost half (62/126, 49.21%) of outcomes were reported only once; the most frequently reported outcome was proportion of patients with negative SARS-CoV-2. 27 outcomes were provided one or more outcome measurement instruments. 40 (40/126, 31.75%) outcomes were provided one or more measurement time frame. Conclusion: Outcome reporting in protocols of clinical trials of COVID-19 is inconsistent. Thus, developing a core outcome set is necessary. Keywords: Outcomes; clinical trials, COVID-19; review.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Protocols\n\n<http://www.comet-initiative.org/Studies/Details/1507>\n\n### Funding Statement\n\nThis work was supported by the National High-level Personnel of Special Support Program [W02020052].\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe data is from public database and does not include identifiable patient data.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031401v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031401v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031401v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/08/2020.03.04.20031401.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.04.20031401v1", "access_rights": "restricted", "authors": ["Ruijin Qiu", "Xuxu Wei", "Mengzhu Zhao", "Changming Zhong", "Chen Zhao", "Jiayuan Hu", "Min Li", "Ya Huang", "Songjie Han", "Tianmai He", "Jing Chen", "Hongcai Shang"]}